Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA:600420)
China · Delayed Price · Currency is CNY 10.52
+0.08 (0.77%)
Feb 3, 2026, 3:00 PM CST
SHA:600420 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 9,363 | 10,770 | 11,787 | 12,810 | 13,756 |
Other Revenue | - | 167.77 | 282.98 | 149.79 | 189.06 |
| 9,363 | 10,938 | 12,070 | 12,959 | 13,945 | |
Revenue Growth (YoY) | -14.39% | -9.38% | -6.86% | -7.07% | 11.06% |
Cost of Revenue | - | 6,822 | 7,538 | 8,091 | 7,909 |
Gross Profit | 9,363 | 4,116 | 4,532 | 4,868 | 6,036 |
Selling, General & Admin | - | 1,921 | 2,906 | 3,414 | 4,220 |
Research & Development | - | 565.65 | 562.24 | 517.14 | 584.97 |
Other Operating Expenses | 8,049 | 95.76 | 115.06 | 113.17 | 128.31 |
Operating Expenses | 8,049 | 2,580 | 3,565 | 4,027 | 4,958 |
Operating Income | 1,314 | 1,536 | 967.35 | 841.24 | 1,078 |
Interest Expense | - | -36.89 | -57.88 | -107.31 | -110.47 |
Interest & Investment Income | - | 151.08 | 136.48 | 61.69 | 48.84 |
Currency Exchange Gain (Loss) | - | 40.61 | 28.44 | 98.32 | -32.65 |
Other Non Operating Income (Expenses) | 14.19 | -2.01 | -4.09 | -4.23 | -5.75 |
EBT Excluding Unusual Items | 1,328 | 1,688 | 1,070 | 889.71 | 978 |
Impairment of Goodwill | - | - | - | - | -132.15 |
Gain (Loss) on Sale of Investments | - | - | - | - | -24.04 |
Gain (Loss) on Sale of Assets | - | -31.31 | -31.85 | -1.1 | 0.2 |
Asset Writedown | - | -28.26 | -13.13 | -4.93 | -10.81 |
Other Unusual Items | - | 44.21 | 71.24 | 100.45 | 107 |
Pretax Income | 1,328 | 1,673 | 1,097 | 984.12 | 918.21 |
Income Tax Expense | 383.82 | 340.97 | 131.95 | 116.63 | 97.06 |
Earnings From Continuing Operations | 944.38 | 1,332 | 964.61 | 867.48 | 821.15 |
Minority Interest in Earnings | - | -248.46 | -272.73 | -239.69 | -252.87 |
Net Income | 944.38 | 1,084 | 691.88 | 627.79 | 568.28 |
Net Income to Common | 944.38 | 1,084 | 691.88 | 627.79 | 568.28 |
Net Income Growth | -12.85% | 56.62% | 10.21% | 10.47% | -12.41% |
Shares Outstanding (Basic) | 1,341 | 1,341 | 1,273 | 1,027 | 1,027 |
Shares Outstanding (Diluted) | 1,341 | 1,341 | 1,273 | 1,156 | 1,178 |
Shares Change (YoY) | 0.01% | 5.31% | 10.13% | -1.82% | -0.14% |
EPS (Basic) | 0.70 | 0.81 | 0.54 | 0.61 | 0.55 |
EPS (Diluted) | 0.70 | 0.81 | 0.54 | 0.54 | 0.48 |
EPS Growth | -12.86% | 48.72% | 0.07% | 12.52% | -12.29% |
Free Cash Flow | - | 2,036 | 1,363 | 2,548 | 1,158 |
Free Cash Flow Per Share | - | 1.52 | 1.07 | 2.20 | 0.98 |
Dividend Per Share | - | 0.300 | 0.100 | 0.100 | 0.100 |
Dividend Growth | - | 200.00% | - | - | - |
Gross Margin | 100.00% | 37.63% | 37.55% | 37.57% | 43.28% |
Operating Margin | 14.03% | 14.04% | 8.02% | 6.49% | 7.73% |
Profit Margin | 10.09% | 9.91% | 5.73% | 4.84% | 4.08% |
Free Cash Flow Margin | - | 18.62% | 11.29% | 19.66% | 8.31% |
EBITDA | 2,066 | 2,288 | 1,786 | 1,671 | 1,857 |
EBITDA Margin | 22.07% | 20.92% | 14.80% | 12.90% | 13.31% |
D&A For EBITDA | 752.01 | 752.01 | 818.89 | 830.01 | 778.52 |
EBIT | 1,314 | 1,536 | 967.35 | 841.24 | 1,078 |
EBIT Margin | 14.03% | 14.04% | 8.01% | 6.49% | 7.73% |
Effective Tax Rate | 28.90% | 20.38% | 12.03% | 11.85% | 10.57% |
Revenue as Reported | - | 10,938 | 12,070 | 12,959 | 13,945 |
Advertising Expenses | - | 6.18 | 4.64 | 3.29 | 7.1 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.